Preclinical Study Shows Potential for Type 1 Diabetes Treatment
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aro Biotherapeutics presented preclinical findings at the Breakthrough T1D Clinical & Research Congress. The presentation highlighted the therapeutic potential of its CD71 Centyrin - IFIH1 siRNA conjugate for treating Type 1 diabetes. Testing in a murine model of Type 1 diabetes showed reduced blood glucose levels, delayed disease onset, and improved survival.
From manilatimes.net
Why it matters
The findings detail the use of a targeted short-interfering RNA (siRNA) medicine to treat Type 1 diabetes. The conjugate was designed to deliver siRNA to CD71 receptor-expressing cells, including immune cells and the pancreas.
From manilatimes.net
Who's involved
- BreakthroughHost of the Breakthrough T1D Clinical & Research Congress